Samsung Biologics (KRX:207940) entered the antibody-drug conjugate (ADC) sector, with its new 500-liter ADC production facility in Songdo, Incheon, set to commence operations in February, The Korea Herald reported Thursday.
ADCs combine monoclonal antibodies targeting cancer cells with potent drugs to improve therapeutic precision and efficacy, the report said.
The Songdo facility is a four-story unit that features large-scale purification capabilities and streamlined quality control systems, it said.
The company has deepened its collaboration with LigaChem Biosciences (KOSDAQ:141080), signing a material transfer agreement in June 2024 and committing to more than three ADC projects in 2025, the report said.
Shares of Samsung Biologics fell more than 1% in recent trade on Friday while those of LigaChem Biosciences fell nearly 1%.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.